Combination treatment of HDAC inhibitors with immune checkpoint inhibitors is widely investigated recently [54] and gives promising results in triple negative breast cancer [55] and in melanoma cells [56, 57]. This evidence concerns the gene HDAC9 and triple-negative breast carcinoma.